Tirzepatide Once Weekly for the Treatment of Obesity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Effects of different Metabolic Bariatric Surgeries in Testosterone Levels: A Systematic Review and Meta-Analysis.Obesity surgery · 2025
   Pooled it
2. Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.International journal of clinical pharmacy · 2024
   Pooled it
3. Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.The Journal of clinical endocrinology and metabolism · 2026
   Observational
4. Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.Advances in therapy · 2026
   Article
5. Cryo-EM structures of GPR75 reveal an occluded orthosteric pocket challenging conventional drug discovery paradigms for an anti-obesity target.Acta pharmacologica Sinica · 2026
   Article
6. Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis.JHEP reports : innovation in hepatology · 2026
   Article
7. GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.Frontiers in medicine · 2026
   Review
8. Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.Drug, healthcare and patient safety · 2026
   Article
9. From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma.Hepatology communications · 2025
   Review
10. Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.Molecular medicine (Cambridge, Mass.) · 2025
    Article
11. Obesity: pathophysiology and therapeutic interventions.Molecular biomedicine · 2025
    Review
12. Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients with Obesity.Nutrients · 2025
    Article
13. SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction.eLife · 2024
    Article
14. Imaging of Sarcopenia in Type 2 Diabetes Mellitus.Clinical interventions in aging · 2024
    Review

Corrections and comments

• Commented on by
  Tirzepatide Once Weekly for the Treatment of Obesity. Reply.2022
• Comment on
  Tirzepatide Once Weekly for the Treatment of Obesity.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as